Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Blood (2023) 142 (Supplement 1): 990.

https://doi.org/10.1182/blood-2023-177823

Published: 2023

Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan

Blood (2023) 142 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2023-178231

Published: 2023

Journal Articles

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

Seda S. Tolu, Alexander Sanjurjo, David Destephano, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2023-177722

Published: 2023

Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 6118.

https://doi.org/10.1182/blood-2023-180875

Published: 2023

Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David J Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Yingxue Chen, Jade Chen, Rajat Bannerji, Apoorva Kapopara, Attila Szanto, Franck Morschhauser

Blood (2023) 142 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2023-179910

Published: 2023

Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual

Blood (2023) 142 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2023-179271

Published: 2023

Journal Articles

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Hua-Jay J. Cherng, Xiaojing Yang, Ryan Yancey, Christian A Gordillo, Ted B. Piorczynski, Hei T. Chan, Kenneth N. Ofori, Govind Bhagat, Andrea Califano, Barbara Pro, Keith Booher, Jennifer E. Amengual, Ran Reshef, Abu A. I. Sina

Blood (2023) 142 (Supplement 1): 4371.

https://doi.org/10.1182/blood-2023-178376

Published: 2023

Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual

Blood (2023) 142 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2023-186639

Published: 2023

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

How I treat posttransplant lymphoproliferative disorder

Jennifer E. Amengual, Barbara Pro

Blood (2023) 142 (17): 1426–1437.

https://doi.org/10.1182/blood.2023020075

Published: 2023

Journal Articles

Queen's gambit: response-adapted win in CAYA with cHL

Seda S. Tolu, Jennifer E. Amengual

Blood (2023) 141 (17): 2037–2038.

https://doi.org/10.1182/blood.2022019339

Published: 2023

Journal Articles

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Evelyn Orlando, Maegan Ford, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 12085–12086.

https://doi.org/10.1182/blood-2022-158050

Published: 2022

Journal Articles

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Alexander Coltoff, Andrew H. Lipsky, Todd L. Rosenblat, Jennifer E. Amengual, Mark L Heaney, Joseph G. Jurcic, Nicole Lamanna

Blood (2022) 140 (Supplement 1): 9893–9895.

https://doi.org/10.1182/blood-2022-167191

Published: 2022

Journal Articles

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Connie Lee Batlevi, Gilles Salles, Steven I. Park, Tycel J. Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John P. Leonard, Manu Sondhi, Yingxue Chen, Pamela L. Slatcher, Richard Lin, Attila Szanto, Sara Abbadi, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 2296–2298.

https://doi.org/10.1182/blood-2022-166991

Published: 2022

Journal Articles

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Maegan Ford, Evelyn Orlando, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 3794–3795.

https://doi.org/10.1182/blood-2022-163813

Published: 2022

Journal Articles

Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder

Maegan Ford, Evelyn Orlando, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 3777–3778.

https://doi.org/10.1182/blood-2022-160147

Published: 2022

Journal Articles

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Brian Estrella, Manuel A Pazos, II, Edd C Ricker, Yun Kyoung Ryu, Ted B. Piorczynski, Yuxuan Liu, Seda Tolu, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 358–359.

https://doi.org/10.1182/blood-2022-166929

Published: 2022

Journal Articles

A Tet-a-Tet in T follicular helper cell lymphoma

Jennifer E. Amengual

Blood (2022) 140 (18): 1919–1921.

https://doi.org/10.1182/blood.2022017807

Published: 2022

Journal Articles

Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL

Edd C Ricker, Brian Estrella, Manuel A Pazos, II, Jennifer E. Amengual

Blood (2021) 138 (Supplement 1): 2410.

https://doi.org/10.1182/blood-2021-153460

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2021-148199

Published: 2021

NARROW

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

How I treat posttransplant lymphoproliferative disorder

Queen's gambit: response-adapted win in CAYA with cHL

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Treatment Modalities Effect on Outcome in Post-Transplant Lymphoproliferative Disorder

Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder

First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

A Tet-a-Tet in T follicular helper cell lymphoma

Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only